Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2019
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 52 citations in OpenAlex.
- Factors Influencing Treatment Outcomes in a Randomized Clinical Trial for Gambling Disorder: A Secondary Analysis.European addiction research · 2026Trial
- Intranasal Naloxone During Recurrent Exercise in Individuals with Type-1 Diabetes Mellitus: Evaluation of the Clinical Predictors of Pharmacokinetics and Exposure-Response.Journal of clinical pharmacology · 2025Trial
- Trial
- Quantitative μ-Opioid Receptor PET with [Pharmaceutics · 2026Article
- Targeting Mu Opioid Receptor Neurons of the Habenula to Limit Naloxone Aversion.Biological psychiatry · 2026Article
- Exploring wanting and liking during positive human-animal interactions.Psychopharmacology · 2026Article
- Inter-individual variability of neurotransmitter receptor and transporter density in the human brain.Brain structure & function · 2026Article
- Combining the alpha-2 adrenergic agonist clonidine with naloxone rescues fentanyl-induced physiologic dysfunction and increases survival.bioRxiv : the preprint server for biology · 2025Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Reported outcomes from a community naloxone training and distribution program.Drug and alcohol dependence reports · 2025Article
- Ex-vivo Imaging of Glial Energy Metabolism in the Neonatal Mouse Brain during Convulsive Seizures with Intranasal Radiotracer Administration.Molecular imaging and biology · 2025Article
- Intranasal overdose reversal formulations: a rapid review of available agents.Pain management · 2025Review
- Article
- High-dose naloxone formulations are not as essential as we thought.Harm reduction journal · 2024Review
- Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.Clinical pharmacokinetics · 2024Review
- Amphetamine-induced dopamine release in rat: Whole-brain spatiotemporal analysis with [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024Article
- Are carfentanil and acrylfentanyl naloxone resistant?Frontiers in psychiatry · 2024Article
- Re-examining Naloxone Pharmacokinetics After Intranasal and Intramuscular Administration Using the Finite Absorption Time Concept.European journal of drug metabolism and pharmacokinetics · 2023Article
- Preliminary Evidence for the Sequentially Mediated Effect of Racism-Related Stress on Pain Sensitivity Through Sleep Disturbance and Corticolimbic Opioid Receptor Function.The journal of pain · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal spray formulations of naloxone, a mu-opioid receptor (MOR) antagonist, are currently used for the treatment of opioid overdose. They may have additional therapeutic utility also in the absence of opioid agonist drugs, but the onset and duration of action at brain MORs have been inadequately characterized to allow such projections. This study provides initial characterization of brain MOR availability at high temporal resolution following intranasal (IN) naloxone administration to healthy volunteers in the absence of a competing opioid agonist. Fourteen participants were scanned twice using positron emission tomography (PET) and [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.